NVO held its Investor Day webcast yesterday—lots of interesting slides on the diabetes market, especially as it pertains to The Global Demographic Tailwind:
10% of adults in China are diabetic (#msg-48221898), so there’s a really big upside here for somebody.
Did NVO discuss the ultra-fast acting insulins, either their own candidates or buzz about any desire to in-license such a candidate? I'm now long BIOD and they could sure use a big pharma partner in the diabetes space.
Market Data 
Markets 
AI
